Versant Ventures has launched Granite Bio with $100 million in funding, advancing two novel antibody drugs targeting inflammatory conditions through its Ridgeline Therapeutics initiative.
Seraxis received FDA IND allowance for SR-02, a stem cell-derived islet replacement therapy, marking a potential functional cure for insulin-requiring diabetes.